weekly_roundup
BioTechSign Daily Catalyst Roundup - November 10, 2026
Top BioTechSign catalyst names today: EYPT, PRAX, NKTR, NUVB, CAPR, BBIO. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 10, 2026
Daily Biotech Catalyst Digest: November 10, 2026
EYPT leads the current BioTechSign screen at 84.2/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 84.2 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| PRAX | Praxis Precision Medicine | 76.8 | B | clinical activity 100%, PDUFA timing 75%, short interest 50% |
| NKTR | Nektar Therapeutics | 74.4 | B | publication signal 100%, short interest 90%, clinical activity 75% |
| NUVB | Nuvation Bio | 73.6 | B | clinical activity 88%, PDUFA timing 75%, short interest 70% |
| CAPR | Capricor Therapeutics, Inc. | 70.3 | B | PDUFA timing 100%, publication signal 100%, short interest 90% |
| BBIO | BridgeBio Pharma | 69.1 | B | publication signal 100%, clinical activity 100%, PDUFA timing 90% |
Recent Grade-Change Queue
- AMGN (Amgen Inc) currently grades D with a 39.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 75%, dilution risk 10%.
- ARGX (argenx SE) currently grades F with a 17.4/100 catalyst score. Main inputs: publication signal 100%, dilution risk 15%, short interest 10%.
- JAZZ (Jazz Pharmaceuticals plc) currently grades F with a 23.5/100 catalyst score. Main inputs: publication signal 100%, PDUFA timing 35%, short interest 30%.
- RNAC (Cartesian Therapeutics, Inc.) currently grades D with a 43.8/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 38%.
- GRFS (Grifols SA) currently grades F with a 20.2/100 catalyst score. Main inputs: publication signal 100%, dilution risk 19%, short interest 10%.
- RCKT (Rocket Pharmaceuticals) currently grades F with a 28.4/100 catalyst score. Main inputs: publication signal 100%, dilution risk 54%, short interest 50%.
- RZLT (Rezolute, Inc.) currently grades D with a 37.5/100 catalyst score. Main inputs: short interest 70%, dilution risk 57%, clinical activity 50%.
- IBRX (ImmunityBio, Inc.) currently grades C with a 62.5/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, PDUFA timing 75%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.